A dual-reporter mouse for therapeutic discovery in Angelman syndrome
JCI Insight · 2026
DOI: 10.1172/jci.insight.197028 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Hanna Vihma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Physiology, Neuroscience Center. Hauptthemen laut MEDLINE: Angelman Syndrome, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Angelman syndrome is a neurodevelopmental disorder caused by loss of the maternal UBE3A allele, the sole source of UBE3A in mature neurons owing to epigenetic silencing of the paternal allele. Although emerging therapies are being developed to restore UBE3A expression by activating the dormant paternal UBE3A allele, existing mouse models for such preclinical studies have limited throughput and utility, creating bottlenecks for both in vitro therapeutic screening and in vivo characterization. To address this, we developed the Ube3a -INSG dual-reporter knockin mouse, in which an IRES-Nanoluciferase-T2A-Sun1-sfGFP (INSG) cassette was inserted downstream of the endogenous Ube3a stop codon. The INSG model preserves UBE3A protein levels and function while enabling 2 complementary allele-specific readouts: Sun1-sfGFP and Nanoluciferase. We show that Sun1-sfGFP, a nuclear envelope–localized reporter, enables single-cell fluorescence analysis, whole-brain light-sheet imaging, and nuclear quantification by flow cytometry. Further, Nanoluciferase supports high-throughput luminescence assays for sensitive pharmacological profiling in cultured neurons and noninvasive in vivo bioluminescence imaging for pharmacodynamic assessment. By combining scalable screening, cellular analysis, and real-time in vivo monitoring in a single model, the Ube3a -INSG dual-reporter mouse provides a powerful platform to accelerate therapeutic development centered on UBE3A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Physiology, Neuroscience Center.
- Animal Models Core.
- Department of Genetics, and.
- Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Förderung
- NICHD NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke
- NIH Office of the Director
- North Carolina Biotech Center
Zitieren
APA
Vihma, H., James, L. M., Nourie, H. C., Smith, A. L., Liang, S., Friar, C. A., Vulli, T., Xing, L., Cowley, D. O., Burette, A. C., & Philpot, B. D. (2026). A dual-reporter mouse for therapeutic discovery in Angelman syndrome. JCI Insight. https://doi.org/10.1172/jci.insight.197028
Vancouver
Vihma H, James LM, Nourie HC, Smith AL, Liang S, Friar CA, et al. A dual-reporter mouse for therapeutic discovery in Angelman syndrome. JCI Insight. 2026. doi:10.1172/jci.insight.197028
BibTeX
@article{Vihma2026,
author = {Vihma, Hanna and James, Lucas M and Nourie, Hannah C and Smith, Audrey L and Liang, Siyuan and Friar, Carlee A and Vulli, Tasmai and Xing, Lei and Cowley, Dale O and Burette, Alain C and Philpot, Benjamin D},
title = {A dual-reporter mouse for therapeutic discovery in Angelman syndrome},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.197028}
}
EUVIMED